NeoGenomics, Inc.
NEO · Price history
Price at last available close
$17.99
−$0.75 (-4.00%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About NeoGenomics, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers.
How they make money
NeoGenomics generates revenue by providing oncology diagnostic testing and consultative services to healthcare providers and pharmaceutical companies. The company charges fees for technical laboratory services and professional interpretation of test results by pathologists and molecular experts, with revenue growth driven by test volumes, test mix, and reimbursement initiatives.
Products & services
Oncology diagnostic testing services including molecular testing, cytogenetics, fluorescence in-situ hybridization (FISH), and immunohistochemistry (IHC), alongside professional pathology consultation services.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Laboratory equipment and reagent manufacturers — The company relies on various third-party suppliers for laboratory equipment, diagnostic reagents, and consumables necessary for performing oncology tests.Source
Strengths
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
24
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
37
Poor
Financial Strength
61
Business Quality / Moat
48
Management
0
Growth Quality
28
Risk / Durability
20
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
27
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
41/100
Building Historical Record
Model Score 41/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Debt service risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for NEO
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can NEO maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can NEO fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Is NEO's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for NEO to reach sustainable profitability?
- •What future growth or profitability would be needed to justify NEO's current valuation?
Essential Investment Snapshot
Wall Street Score
24
Opportunity Score
27
Market Cap
$2.34B
P/E Ratio
-42.1
EPS
$-0.40
52-Week High
$20.15
52-Week Low
$7.07
Beta
1.78
Analyst Target
$23.50
Shares Outstanding
128.1M
Total Revenue
$766.3M
Total Debt
$448.4M
Dividend
No current dividend
Liquidation Value / Share
$6.14
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Elevated movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for NEO
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-17.6x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on NEO.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Comprehensive oncology diagnostic test menu.
- +Expert pathology and molecular interpretation capabilities.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Diagnostics & Research industry.
- −Dependence on third-party reimbursement and changes in healthcare policy.
- −Operational risks associated with laboratory acquisitions and integration.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
4 historical score records availablePrevious Score
28
Oct 8, 2026
Change
-4.1
points
Current Score
24
Oct 27, 2026
Category Changes
NEO decreased 4.1 points because Revenue declined by 15.6 points, Asset declined by 26.8 points, Buffett declined by 7.2 points.
Negative Contributors
- − Revenue declined by 15.6 points
- − Asset declined by 26.8 points
- − Buffett declined by 7.2 points
Projected Score
Projected Score
21
Projected Change
-3.0 points
Preliminary comparable-period financial changes suggest decline of approximately 3.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$17.99
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $766.3M | $727.3M | $660.6M | $591.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $437.4M | $444.8M | $370.5M | $347.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $328.9M | $282.5M | $290.1M | $244.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $38.2M | $37.1M | $31.2M | $27.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $359.1M | $365.3M | $310.5M | $280.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $395.1M | $348.6M | $382.2M | $352.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $12.9M | -$38.7M | -$1.5M | -$17.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$66.2M | -$66.1M | -$92.1M | -$107.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $2.6M | $3.8M | $6.6M | $6.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$54.5M | -$110.3M | -$80.7M | -$97.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | -$2.7M | -$2.2M | -$1.9M | -$9.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$51.9M | -$108.0M | -$78.7M | -$88.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.40 | $-0.84 | $-0.62 | $-0.70 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 130M | 128M | 127M | 126M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 131M | 128M | 127M | 126M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$201.7M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$0.02
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+8.9%
Cash Change
-5.9%
Margin Change
+26.0 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
What Weakened
- Cash position declined
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, net income margin. Pressure indicators included EPS growth, cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 11.2%. EPS declined 105.7%. Cash declined 5.9%. Total debt increased 8.9%. Net income margin improved by 26.0 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Diagnostics & ResearchNews
NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus
NeOnc's Boldest Test Yet: Child's Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone
NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi
NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
Rumor Mill · NEO
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial